Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Ameloblastoma × dabrafenib × Clear all

Phase

Phase 2 2 Phase 3 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 7 Neoplasms 3 Skin Neoplasms 1 Sarcoma 1 Refractory Differentiated Thyroid Gland Carcinoma 1 Neoplasm Metastasis 1 Fever 1 Differentiated Thyroid Cancer (DTC) 1 Ameloblastoma 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06264778 2024-02-20

Exploration of Fenestration Decompression Combined With Dalafenib in the Treatment of BRAF Mutant Ameloblastoma

Shandong University

Phase 3 Unknown

Ameloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡